Stem Cell Therapeutics Corp. Announces Appointment of Barry Herring as New Chief Financial Officer

CALGARY, ALBERTA, Jan 12 (MARKET WIRE) --
Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE: SSS) today announced
that Mr. Barry Herring has been appointed as the new Vice President of
Finance and Chief Financial Officer (CFO), effective January 1, 2009. Mr.
Mark Wayne has resigned as CFO but will remain on the Board of Directors
of SCT as Chairman.

Mr. Herring has 25 years experience as an accounting executive for
companies in Canada and the United States. He has been a senior executive
in public and private corporations within the energy and mining sector.
Prior to joining SCT, Mr. Herring was the President, CFO and Director of
Atlas Minerals Inc. Prior thereto he was the CFO of Velo Energy Ltd., a
start-up Oil and Gas Exploration Company. He has served as Vice President
of Finance and CFO for the following companies, TerraWest Energy Corp.,
Hawker Resources Inc., and Southward Energy Ltd.

Mr. Herring became a Chartered Accountant in 1983 from the Institute of
Chartered Accountants of Alberta. He started his career in accounting in
1981 at Price Waterhouse. In 1987, Mr. Herring joined Oakwood Petroleum
and worked as a corporate accountant until joining Calpine Natural Gas
Ltd. in 1989 where he held increasingly senior positions until his
departure in 2001.

In addition to his corporate experience, Mr. Herring has taught
accounting and tax at the post secondary level and chaired several
committees on Information Systems development and implementation.

Dr. Alan Moore, President and CEO of SCT commented as follows:

"We are very excited to add Mr. Barry Herring to the SCT executive team.
I feel his knowledge and expertise in finance as well as his experience
with start-up companies will be a great asset to the Company."

SCT has issued 800,000 stock options to Mr. Herring at an exercise price
of C$0.10 per share in connection with his appointment to the Executive
team. These options will expire no later than January 1, 2014 subject to
applicable vesting provisions. These options were awarded in accordance
with the Corporations Stock Option Plan.

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a
Canadian public biotechnology company (TSX VENTURE: SSS) focused on the
development and commercialization of drug-based therapies to treat
central nervous system diseases. SCT is a leader in the development of
therapies that utilize drugs to stimulate a patient's own resident stem
cells. The Company's programs aim to repair neurological function lost
due to disease or injury. SCT's extensive patent portfolio of owned and
licensed intellectual property supports the potential expansion into
future clinical programs in numerous neurological diseases such as
traumatic brain injury, multiple sclerosis, Huntington's disease,
Alzheimer's disease, ALS.

These securities have not been registered under the United States
Securities Act of 1933, as amended, or the securities laws of any state,
and may not be offered or sold within the United States or to, or for the
account or benefit of U.S. persons unless an applicable exemption from
U.S. registration requirements is available.

Except for historical information, this press release may contain
forward-looking statements, which reflect the Company's current
expectation regarding future events. These forward-looking statements
involve risk and uncertainties, which may cause but are not limited to,
changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact of
competitive products and pricing, new product development, uncertainties
related to the regulatory approval process and other risks detailed from
time to time in the Company's ongoing quarterly and annual reporting.

The TSX Venture Exchange does not accept responsibility for the adequacy
or accuracy of this release.

Contacts:
Stem Cell Therapeutics Corp.
Alan Moore, PhD
President and CEO
(403) 245-5495 ext.224
Email: amoore@stemcellthera.com

Stem Cell Therapeutics Corp.
Chloe Douglas-Crampton
Investor Relations
(403) 245-5495 ext. 221
Email: crampton@stemcellthera.com
Website: www.stemcellthera.com

Copyright 2009, Market Wire, All rights reserved.

-0-